Publications by authors named "Matthieu Gracia"
Background: Radiolabeled-antibodies usually display non-specific liver accumulation that may impair image analysis and antibody biodistribution. Here, we investigated whether Fc silencing influenced antibody biodistribution. We compared recombinant Zr-labeled antibodies (human IgG1 against different targets) with wild-type Fc and with mutated Fc (LALAPG triple mutation to prevent binding to Fc gamma receptors; FcγR).
View Article and Find Full Text PDFArticle Synopsis
- Palbociclib is considered suitable for therapeutic drug monitoring due to its narrow therapeutic range and high incidence of serious side effects like neutropenia.
- A clinical trial involving 58 patients showed a correlation between palbociclib plasma levels and the occurrence of high-grade neutropenia, especially in those with lower neutrophil counts at treatment start.
- Drug interactions significantly impacted palbociclib plasma levels, with certain co-treatments increasing or decreasing concentrations, but these interactions did not significantly affect the rates of high-grade neutropenia.
Article Synopsis
- Antibody-based medicines are really important, with over 120 types approved or being looked at in the US and EU, especially after the COVID-19 pandemic.
- Scientists are trying to find better ways to deliver these antibodies into the body so that they work better and are easier for patients to receive.
- However, there are challenges in figuring out how antibodies get through different barriers in the body to reach their targets, and researchers are working on strategies to improve this for better treatments with fewer side effects.
Monoclonal antibody (mAb)-based immunotherapy is booming in oncology. In 2020, more than 40% of FDA (Food and Drug Administration)-approved antibodies (34 out of 84 antibodies, according to The Antibody Society) have an indication for cancer therapy. In contrast to standard chemotherapy, they demonstrate a much better safety profile for patients.
View Article and Find Full Text PDFThe CDK4/6 inhibitors palbociclib and ribociclib are kinase inhibitors used in association with hormonal therapy for the management of patients with metastatic breast cancer. Like most kinase inhibitors, therapeutic drug monitoring may be used for personalize their dosage. To this aim, we developed and validated a sensitive and specific HPLC-MS/MS method for palbociclib and ribociclib quantification in blood samples.
View Article and Find Full Text PDF